Where there's hope, there's action

Where there's hope, there's action.

SpringWorks Therapeutics is a new type of therapeutic development company—a springboard to get more treatments to more patients, faster.

 

We are a different type of therapeutic development company purpose-built for the 21st century. SpringWorks Therapeutics is on a mission to connect scientists, biopharmaceutical partners, patient groups, funders and philanthropists to deliver promising, transformative science to underserved patients. Our name symbolizes our mission-driven approach to therapeutic development—we’re springing into action to deliver treatments to people who are in urgent need.

The  gap

Today's rapid pace of scientific breakthroughs, combined with greater productivity in early research and development, means that biopharmaceutical companies have more development programs than they can move forward. Many of these investigational therapies hold significant promise for patients.
 

The  hope

SpringWorks Therapeutics was originally conceived by Pfizer to provide these innovative treatments an additional avenue for development and giving hope to those who, until now, have been underserved.
 

The  commitment

We’re committed to ensuring transparency, honesty and respect in all aspects of our work with patients, researchers, regulators, funders and other partners.
 

  
Approach

SpringWorks Therapeutics is passionate about developing medicines for underserved patient populations. Today, we begin our journey with four clinical programs licensed from Pfizer focused on four diseases, none of which currently have a cure.

Our  Pipeline

Therapeutic Area
Compound
Indication
Phase 1
Phase 2
Phase 3
 
 
Therapeutic
Oncology
 
Compound
Nirogacestat (Gamma Secretase Inhibitor)
 
 
Indication
Desmoid Tumor
 
Phase 1
Phase 2
Phase 3
 
 
 
 
 
Therapeutic
Oncology/Neurology
 
Compound
MEK 1/2 Inhibitor
 
Indication
NF1
 
Phase 1
Phase 2
Phase 3
 
 
 
 
 
Therapeutic
Rare Genetic Disease
 
Compound
Senicapoc (Gardos Channel Blocker)
 
 
Indication
Hereditary Xerocytosis
 
Phase 1
Phase 2
Phase 3
 
 
 
 
 
Therapeutic
NeuroPsychiatry
 
Compound
FAAH Inhibitor
 
Indication
Post Traumatic Stress Disorder
 
Phase 1
Phase 2
Phase 3
 
 
 
 
 
 
 
 

Our team

Daniel S. Lynch
Daniel S. Lynch
Executive Chairman
Lara Sullivan, MD, MBA
Lara S. Sullivan, M.D., MBA
President and Founder
Saqib Islam
Saqib Islam, JD
Chief Financial Officer and Chief Business Officer
Stephen Squinto
Stephen Squinto, PH.D.
Acting Head of Research and Development
L. Mary Smith, Ph.D.
L. Mary Smith, Ph.D.
Vice President Clinical Research and Development
Paul Barclay, Ph.D.
Paul Barclay, Ph.D.
Vice President Project Management
 

Board of Directors

Daniel S. Lynch
Executive Chairman
Carl L. Gordon, Ph.D., CFA
Partner, OrbiMed
Peter Keen
Trustee, LifeArc
Freda Lewis-Hall, M.D., DFAPA
EVP and Chief Medical Officer, Pfizer
Deval Patrick
Managing Director, Bain Capital Double Impact
Jeffrey Schwartz
Managing Director, Bain Capital Life Sciences
Stephen Squinto, Ph.D.
Acting Head of Research and Development
Lara S. Sullivan, M.D.
President and Founder

Our Partners

Pfizer
BainCapital
OrbiMe
LifeArc
The Desmoid Tumor Research Foundation
Children’s Tumor Foundation
Cohen Veterans Bioscience

UCDavis - University of California
Boston Children’s Hospital
Alzheimer’s Drug Discovery Foundation

Connect with Us

Learn more about SpringWorks Therapeutics by contacting us.
Media relations or PR inquiries:
kengleman@purecommunications.com
 
General Info or Inquiries:
info@springworkstx.com
 
OUR LATEST NEWS:
SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs